Calyx plans to partner with BAMF Health on an initiative to speed the development of radioligand therapies and immune-oncology agents.
The two firms hope that the collaboration will address problems caused by "fragmented service ecosystems," they said.
The project prompting the partnership is an actinium-225 initiative; TerraPower Isotopes will supply the actinium-225 isotopes and BAMF will use its GE HealthCare (GEHC) StarGuide SPECT/CT system and its dosimetry expertise to further enhance the study and application of actinium-225 in radioligand and immune-oncology therapies.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
